P714 Vedolizumab, an adequate option in medically refractory and thiopurine-intolerant inflammatory bowel disease patients

Long‐term efficacy and safety of vedolizumab in patients with inflammatory bowel diseases: A real‐life experience from a tertiary referral center

“…Considering the highly selective character of trial enrollment, it is always fundamental to observe whether real‐life settings support the initially reported results of a new drug . Real‐world publications on this field are accumulating, with some conflicting results, but only a few of them include long‐term evaluation at 1 year with endoscopic assessment . Therefore, we presented an Italian single‐center study on VDZ long‐standing effectiveness and tolerability in patients with UC and CD at a tertiary referral setting.…”

Dose Escalation Patterns of Advanced Therapies in Crohn’s Disease and Ulcerative Colitis: A Systematic Literature Review

“…¤ Studies reporting 5 mg/kg were assumed to have dosing every 8 weeks. Source: [ 27 – 31 , 33 – 37 , 39 – 49 , 51 – 56 , 59 – 80 , 82 – 104 , 106 – 110 , 112 – 133 , 198 – 202 ]

Fig. 3 Most reported dose escalation patterns, Crohn’s disease.

…”

“…‡Including maintenance patterns where only the interval (e.g., q8w) was reported. Source [ 29 – 31 , 33 , 35 – 37 , 39 , 40 , 44 – 49 , 51 – 54 , 59 – 75 , 77 – 83 , 85 – 91 , 95 – 97 , 99 , 101 , 103 – 108 , 110 , 111 , 114 – 118 , 120 – 131 , 133 – 139 , 155 , 209 – 211 , 214 ]

Fig. 4 Most reported dose patterns at the end of follow-up in Crohn’s disease.

…”

“…All studies conducted within NA ( n = 3/3) [ 46 , 47 , 106 , 107 ] or ONA ( n = 8/8) [ 42 – 45 , 48 , 49 , 51 , 52 , 103 , 108 – 110 ] reported initial maintenance dosing of 300 mg every 8 weeks with a median proportion of 100% (Fig. 2 ).…”

“…The most common dose escalation pattern observed during follow-up was from 300 mg every 8 weeks to every 4 weeks [median proportion: 18% (range 8–27%) in NA studies; 33% (range 12–79%) in studies ONA] (Fig. 3 ) [ 44 – 49 , 51 , 52 , 103 , 106 , 107 , 109 – 111 ].…”